Risk of upper gastrointestinal tract events in risedronate users switched to alendronate.
about
The efficacy and safety of weekly 35-mg risedronate dosing regimen for Chinese postmenopausal women with osteoporosis or osteopenia: 1-year data.A critical review of brand and generic alendronate for the treatment of osteoporosis.Safety of long-term bisphosphonate therapy for the management of osteoporosis.
P2860
Risk of upper gastrointestinal tract events in risedronate users switched to alendronate.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Risk of upper gastrointestinal tract events in risedronate users switched to alendronate.
@en
Risk of upper gastrointestinal tract events in risedronate users switched to alendronate.
@nl
type
label
Risk of upper gastrointestinal tract events in risedronate users switched to alendronate.
@en
Risk of upper gastrointestinal tract events in risedronate users switched to alendronate.
@nl
prefLabel
Risk of upper gastrointestinal tract events in risedronate users switched to alendronate.
@en
Risk of upper gastrointestinal tract events in risedronate users switched to alendronate.
@nl
P2093
P1476
Risk of upper gastrointestinal tract events in risedronate users switched to alendronate.
@en
P2093
Bettina Wick-Urban
Michael Steinbuch
Stuart H Ralston
Tahir Masud
Tzuyung D Kou
P2888
P304
P356
10.1007/S00223-010-9401-0
P407
P577
2010-08-29T00:00:00Z
P6179
1053119024